EL7.AI
StocksMedium•4 August 2026•
1 min read

DaVita Reports Lower Revenue Per Treatment, Reaffirms 2026 Annual Forecast

Key Facts

1DaVita reported lower revenue per treatment in the second quarter of 2026.
2The company blamed the decline on falling enrollments in Obamacare plans following the end of pandemic-era subsidies.
3The company reaffirmed its full-year financial forecast despite the current challenges.

Amid shifting dynamics in the U.S. healthcare landscape, DaVita reported a decline in revenue per treatment session during the second quarter of 2026. The company attributed this decrease to falling enrollments in Affordable Care Act (Obamacare) plans following the expiration of pandemic-era subsidies. Despite these headwinds, the healthcare provider reaffirmed its full-year financial forecast, signaling confidence in its ability to navigate the current fiscal year.

The decline highlights a significant shift in the payer mix as government support programs wind down, impacting profitability metrics across the dialysis sector. According to reports, the transition away from subsidized plans has created a challenging environment for per-patient revenue growth. This trend reflects broader sector pressures where regulatory shifts directly influence the financial performance of major healthcare service providers.

Market participants will likely focus on upcoming economic catalysts and the broader impact of interest rate environments on healthcare financing, following the Fed's recent decision to hold rates at 3.75% in late July.